帕罗西汀合并认知心理疗法治疗28例广泛性焦虑对照研究

帕罗西汀在广泛性焦虑症治疗中的效果评价[摘要]目的：探究在广泛性焦虑症治疗中实施帕罗西汀药物的价值。

方法：本院60例广泛性焦虑症患者为样本，在2019.10～2022.12研究时间段当中，随机分组，对照组阿普唑仑片（30例），实验组帕罗西汀（30例）。

统计对比：焦虑情绪评分、不良事件发生率。

结果：在对照组和实验组患者的研究数据进行比较时，我们发现实验组的结果呈现出积极的优化（P＜0.05），与对照组相比具有显著性差异。

结论：帕罗西汀作为治疗广泛性焦虑症的药物，在临床应用中展现出了明显的疗效。

其优势和积极价值得到了广泛认可和充分肯定。

[关键词]帕罗西汀；广泛性焦虑症；治疗效果Evaluation of the efficacy of paxil in the treatment ofgeneralized anxiety disorder[Abstract] Objective: To explore the value of paroxetine in the treatment of generalized anxiety disorder. Methods: 60 patients with generalized anxiety disorder in our hospital were randomly pided into Alprazolam tablets (30 cases) in the control group and paroxetine (30 cases) in the experimental group during the study period from 2019.10to 2022.12. Statistical comparison: anxiety score, incidence ofadverse events. Results: When comparing the study data of patients in the control group and the experimental group, we found that theresults of the experimental group showed a positive optimization (P < 0.05), which had a significant difference compared with the control group. Conclusion: Paroxetine, as a drug for the treatment of generalized anxiety disorder, has shown obvious efficacy in clinicalapplication. Its advantages and positive value have been widely recognized and fully affirmed.[Key words] paroxetine; Generalized anxiety disorder; Therapeutic effect广泛性焦虑症是一种常见的焦虑障碍，可对患者的生活和功能造成一定的危害。

帕罗西汀与阿普唑仑治疗广泛性焦虑症的对照研究摘要】目的通过比较帕罗西汀与阿普唑仑治疗广泛性焦虑症的疗效与副作用，推广帕罗西汀的使用。

方法选择符合CCMD-3诊断标准的广泛性焦虑症病例60例，随机分为帕罗西汀组（30例）与阿普唑仑组（30例）。

分别用帕罗西汀20-60mg/日，阿普唑仑0.8-2.4 mg/日，治疗观察12周。

用汉密尔顿焦虑量表（HAMA）和药物副作用量表（TESS）,评定疗效和药物的不良反应。

结果帕罗西汀与阿普唑仑疗效相当，起效稍慢于阿普唑仑，但中期和长期疗效更持久，没有严重副反应及药物依赖性。

结论帕罗西汀治疗广泛性焦虑症疗效好，副反应轻，患者服药依从性好，又没有成瘾性，可以全程长期使用，减少复发。

【关键词】广泛性焦虑帕罗西汀阿普唑仑【中图分类号】R453 【文献标识码】A 【文章编号】2095-1752（2012）06-0075-02广泛性焦虑症是一种对日常生活事件或想法持续担忧和焦虑的综合征，患者往往清楚地认识到这些担忧是过度和不恰当的，但是不能自控。

它是一种慢性疾病，是最常见的一种焦虑障碍[1]。

它的基本特征为泛化且持续的焦虑，不局限于特定的外部环境。

症状高度变异，但以下主诉常见：总感到神经紧张、发抖、肌肉紧张、出汗、头晕、上腹不适。

患者常诉及自己或亲人很快会有疾病或灾祸临头。

这一障碍在女性更为多见，并常与应激有关，病程不定，但趋于波动并成为慢性。

[2]该病病程长且较少自发缓解，易复发，治疗期一般不宜短于半年，应接受长期治疗，疗程建议为12-24个月，对于一些症状控制比较困难的病人，可以维持用药3-5年或更长，甚至终生[3]。

他给患者造成精神上的痛苦非常大，也使部分病人社会功能受到损害，生活质量明显下降。

所以，医疗干预显得十分重要而且必要。

目前治疗干预广泛性焦虑症的药物主要有三类：一类是苯二氮卓类药，二类是5-HT1A受体部分激动剂（如丁螺环酮、坦度螺酮），三类是具有抗焦虑效果的抗忧郁药（包括SNRIs,SSRIs）。

·489·药品评价 Drug Evaluation 2021,18（08）帕罗西汀联合坦度螺酮治疗中年广泛性焦虑障碍35例临床分析宋颖平1，宋恩霖21.九江市第五人民医院，江西 九江 332000；2.南昌大学基础医学院，江西 南昌 330000［摘要］目的：探讨帕罗西汀联合坦度螺酮治疗中年广泛性焦虑障碍（GAD ）的临床效果。

方法：采用前瞻性随机试验方法，选取2019年4月至2020年5月九江市第五人民医院70例中年GAD 患者作为研究对象，按随机数字表法分为对照组（n =35）和观察组（n =35）。

两组均给予常规治疗，在此基础上对照组采用帕罗西汀治疗，观察组采用帕罗西汀联合坦度螺酮治疗，连续治疗3周。

比较两组治疗前及治疗3周结束时焦虑症状［汉密尔顿焦虑量表（HAMA ）评分］及抑郁症状［汉密尔顿抑郁量表（HAMD ）评分］，并对比两组不良反应情况。

结果：治疗3周结束时，两组HAMA 、HAMD 评分均低于治疗前，且观察组上述评分低于对照组，差异有统计学意义（P ＜0.05）；治疗期间，两组不良反应发生率比较，差异无统计学意义（P >0.05）。

结论：帕罗西汀联合坦度螺酮治疗可减轻中年GAD 患者焦虑、抑郁症状，且未明显增加不良反应。

［关键词］广泛性焦虑症；帕罗西汀；坦度螺酮；不良反应；中年人DOI: 10.19939/ki.1672-2809.2021.08.14Clinical Analysis of Paroxetine Combined with Tandospirone in the Treatment of 35 Case of Middle-aged Generalized Anxiety DisorderSONG Yingping 1, SONG Enlin 21. The Fifth People's Hospital of Jiujiang City, Jiujiang Jiangxi 332000, China;2. School of Basic Medicine, Nanchang University, Nanchang Jiangxi 330000, China.[Abstract] Objective: To explore the clinical effect of paroxetine combined with tandospirone in the treatment of middle-aged generalized anxiety disorder (GAD). Methods: A prospective randomized trial method was used to select 70 middle-aged GAD patients in The Fifth People's Hospital of Jiujiang City from April 2019 to May 2020 as the research objects. According to the random number table method, they were divided into control group (n =35) and observation group (n =35). Both groups were given conventional treatment. On this basis, the control group was treated with paroxetine, and the observation group was treated with paroxetine combined with tandospirone for 3 weeks. The anxiety symptoms [Hamilton Anxiety Scale (HAMA) score ] and depressive symptoms [Hamilton Depression Scale (HAMD) score ] were compared between the two groups before treatment and at the end of 3 weeks of treatment, and the adverse reactions of the two groups were compared. Results: At the end of treatment for 3 weeks, the HAMA and HAMD scores of the two groups were lower than before treatment, and the above scores of the observation group were lower than those of the control group, the difference was statistically significant (P <0.05); during the treatment period, the incidence of adverse reactions between the two groups was compared, the difference was not statistically significant (P >0.05). Conclusion: Paroxetine combined with tandospirone therapy can reduce anxiety and depression symptoms in middle-aged GAD patients without significantly increasing adverse reactions.[Key Words] Generalized anxiety; Paroxetine; Tandospirone; Adverse reactions ; Middle aged作者简介：宋颖平，本科，主治医师。